Janux Therapeutics, Inc. - COMMON STOCK (JANX)

Historical Holders from Q2 2021 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
JANX on Nasdaq
Shares outstanding
60,558,345
Price per share
$13.80
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
65,054,632
Total reported value
$1,589,759,767
% of total 13F portfolios
0%
Share change
-290,409
Value change
-$4,062,602
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
168
Price from insider filings
$13.73
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Janux Therapeutics, Inc. - COMMON STOCK (JANX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 20% $321,192,045 11,971,377 RA Capital Management, L.P. 06 Mar 2025
JANUS HENDERSON GROUP PLC 10% +31% $147,469,714 +$38,459,199 6,033,949 +35% JANUS HENDERSON GROUP PLC 31 Oct 2025
FMR LLC 5.8% $48,484,949 3,512,384 FMR LLC 31 Dec 2025
BlackRock, Inc. 5.7% $85,515,172 3,345,664 BlackRock, Inc. 30 Jun 2025
Paradigm Biocapital Advisors LP 4.9% -18% $67,311,947 -$13,731,530 2,920,258 -17% Paradigm BioCapital Advisors LP 30 Jun 2025
Adage Capital Management, L.P. 4.3% -21% $58,327,500 -$12,398,925 2,525,000 -18% Adage Capital Management, L.P. 30 Jun 2025
As of 30 Sep 2025, Janux Therapeutics, Inc. - COMMON STOCK (JANX) has 168 institutional shareholders filing 13F forms. They hold 65,054,632 shares. .

Top 25 institutional shareholders own 91% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 18% 11,189,693 0% 3.4% $273,476,097
FMR LLC 15% 9,056,062 +1.9% 0.01% $221,330,155
JANUS HENDERSON GROUP PLC 7.8% 4,701,112 +5.4% 0.05% $114,988,241
BlackRock, Inc. 6.2% 3,730,994 +9.6% 0% $91,185,492
Paradigm Biocapital Advisors LP 4.8% 2,920,258 0% 2.1% $71,371,106
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.6% 2,775,000 +9.9% 0.11% $67,821,000
VANGUARD GROUP INC 4% 2,417,104 +10% 0% $59,074,022
STATE STREET CORP 3.1% 1,891,465 +36% 0% $46,227,405
ORBIMED ADVISORS LLC 2.9% 1,766,100 +46% 1% $43,163,484
Point72 Asset Management, L.P. 2.8% 1,710,200 -20% 0.09% $41,797,288
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 1,265,556 -29% 0% $30,931,000
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,083,864 +20% 0% $26,494,551
Woodline Partners LP 1.7% 1,026,938 -17% 0.12% $25,098,365
T. Rowe Price Investment Management, Inc. 1.6% 972,691 0.01% $23,773,000
READYSTATE ASSET MANAGEMENT LP 1.6% 960,379 +38% 1.1% $23,471,663
Logos Global Management LP 1.5% 935,000 -6.5% 2.3% $22,851,400
FRANKLIN RESOURCES INC 1.5% 887,755 -17% 0.01% $21,696,730
Prosight Management, LP 1.4% 865,350 +1.3% 5.1% $21,149,154
Cormorant Asset Management, LP 1.4% 850,000 -43% 1.4% $20,774,000
CITADEL ADVISORS LLC 1.3% 802,784 -35% 0.02% $19,620,041
WELLINGTON MANAGEMENT GROUP LLP 1.2% 701,604 +42% 0% $17,147,203
TANG CAPITAL MANAGEMENT LLC 1.2% 700,000 +250% 0.66% $17,108,000
GOLDMAN SACHS GROUP INC 1.1% 655,108 +88% 0% $16,010,840
First Turn Management, LLC 1.1% 639,699 +43% 2.3% $15,634,244
MPM BIOIMPACT LLC 1% 614,282 0% 2.5% $15,013,052

Institutional Holders of Janux Therapeutics, Inc. - COMMON STOCK (JANX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 137,263 $1,893,755 +$722,531 1,379.78% 4
2025 Q3 65,054,632 $1,589,759,767 -$4,062,602 2,444% 168
2025 Q2 65,439,458 $1,512,559,459 -$28,053,955 2,310% 170
2025 Q1 66,482,123 $1,805,569,824 -$17,648,986 2,700% 179
2024 Q4 64,084,597 $3,430,545,581 +$1,001,929,533 5,354% 212
2024 Q3 45,615,125 $2,072,053,932 +$42,307,800 4,543% 159
2024 Q2 44,686,145 $1,871,580,292 +$107,868,313 4,189% 152
2024 Q1 42,316,581 $1,593,195,886 +$331,813,195 3,765% 118
2023 Q4 33,501,695 $359,539,783 -$17,708,423 1,073% 64
2023 Q3 35,112,124 $353,984,330 +$43,869,870 1,008% 57
2023 Q2 30,508,831 $362,117,364 -$1,132,271 1,187% 54
2023 Q1 30,541,873 $369,527,635 +$18,630,246 1,210% 48
2022 Q4 28,953,942 $381,307,339 -$7,757,462 1,317% 48
2022 Q3 29,548,315 $400,091,845 +$8,915,494 1,354.01% 44
2022 Q2 28,858,606 $352,314,471 +$6,490,678 1,221.01% 39
2022 Q1 28,347,360 $406,524,023 +$10,925,775 1,434% 45
2021 Q4 27,488,754 $541,465,745 +$19,103,046 1,972.99% 45
2021 Q3 26,499,162 $571,210,440 +$36,904,313 2,163.06% 45
2021 Q2 24,743,246 $614,461,000 +$614,460,518 2,495% 29